Boston Scientific Co. (NYSE:BSX) CFO Daniel J. Brennan Sells 15,087 Shares

Boston Scientific Co. (NYSE:BSX - Get Free Report) CFO Daniel J. Brennan sold 15,087 shares of the firm's stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now directly owns 241,451 shares in the company, valued at approximately $25,369,256.57. This represents a 5.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Boston Scientific Stock Performance

Boston Scientific stock traded up $0.06 during trading hours on Monday, hitting $106.20. The company had a trading volume of 3,966,417 shares, compared to its average volume of 6,179,673. Boston Scientific Co. has a one year low of $65.33 and a one year high of $107.17. The firm has a market cap of $156.51 billion, a PE ratio of 84.96, a PEG ratio of 2.79 and a beta of 0.80. The firm has a 50-day moving average of $96.44 and a 200 day moving average of $88.39. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. On average, sell-side analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Piper Sandler lifted their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. StockNews.com upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, January 29th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Thursday, February 6th. Raymond James lifted their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $107.39.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Boston Scientific by 4.4% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock worth $345,205,000 after purchasing an additional 173,034 shares in the last quarter. Mechanics Bank Trust Department bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $415,000. Highland Capital Management LLC acquired a new stake in Boston Scientific during the fourth quarter worth approximately $4,887,000. Brookstone Capital Management increased its stake in Boston Scientific by 23.7% during the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after acquiring an additional 20,307 shares during the period. Finally, Beacon Investment Advisory Services Inc. raised its holdings in Boston Scientific by 31.7% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock valued at $1,744,000 after acquiring an additional 4,702 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.